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Tricarboxylic acid cycleIn this work we studied the mitochondrial-associated metabolic pathways in Huntington's disease (HD)
versus control (CTR) cybrids, a cell model in which the contribution of mitochondrial defects from patients is
isolated. HD cybrids exhibited an interesting increase in ATP levels, when compared to CTR cybrids.
Concomitantly, we observed increased glycolytic rate in HD cybrids, as revealed by increased lactate/pyruvate
ratio, which was reverted after inhibition of glycolysis. A decrease in glucose-6-phosphate dehydrogenase
activity in HD cybrids further indicated decreased rate of the pentose-phosphate pathway. ATP levels of HD
cybrids were signiﬁcantly decreased under glycolysis inhibition, which was accompanied by a decrease in
phosphocreatine. Nevertheless, pyruvate supplementation could not recover HD cybrids' ATP or phospho-
creatine levels, suggesting a dysfunction in mitochondrial use of that substrate. Oligomycin also caused a
decrease in ATP levels, suggesting a partial support of ATP generation by the mitochondria. Nevertheless,
mitochondrial NADH/NADt levels were decreased in HD cybrids, which was correlated with a decrease in
pyruvate dehydrogenase activity and protein expression, suggesting decreased tricarboxylic acid cycle (TCA)
input from glycolysis. Interestingly, the activity of alpha-ketoglutarate dehydrogenase, a critical enzyme
complex that links the TCA to amino acid synthesis and degradation, was increased in HD cybrids. In
accordance, mitochondrial levels of glutamate were increased and alanine was decreased, whereas aspartate
and glutamine levels were unchanged in HD cybrids. Conversely, malate dehydrogenase activity from total
cell extracts was unchanged in HD cybrids. Our results suggest that inherent dysfunction of mitochondria
from HD patients affects cellular bioenergetics in an otherwise functional nuclear background.nd Cell Biology, and Faculty of
3004-504 Coimbra, Portugal.
).
l rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
Huntington's disease (HD) is an autosomal dominant neurodegen-
erative disease, clinically characterized by psychiatric disturbances,
progressive cognitive impairment and choreiform movements. These
symptomsare associatedwith the selective atrophyandneuronal loss in
the striatum and cortex. The disease is caused by a mutation at the 5′
terminal of the huntingtin gene, involving the expansion of CAG triplet,
which encodes for glutamine. Mutant huntingtin may be cleaved by
proteases originating neurotoxic fragments, and also undergoes
conformational changes that lead to the formation of protein aggregates
(Gil and Rego, 2008, for review).Among severalmechanismsof neurodegeneration,mutant huntingtin
is related to mitochondrial dysfunction and relevant changes in energy
metabolism, in both central and peripheral cells which may underlie cell
death (Gil and Rego, 2008). HD patients present high levels of lactate in
both the striatum (Jenkins et al., 1993) and cortex (Jenkins et al., 1993;
Koroshetz et al., 1997), and increased lactate/pyruvate ratio in the
cerebrospinal ﬂuid (CSF) (Koroshetz et al., 1997). Striatal glucose
metabolism was also shown to be decreased, whereas oxygen metabo-
lism is preserved in early symptomaticHDpatients (Powers et al., 2007b).
Moreover, increased glucose metabolism and ATP levels were found in
brain tissue of HD N171-82Qmice, suggesting that the neuronal damage
in HD tissue may be associated with increased energy metabolism at the
tissue level, leading to modiﬁed levels of various intermediary metabo-
lites (Olah et al., 2008). A decrease in mitochondrial complexes II–III
activity and a decrease in succinate oxidation were also found in striatal
tissue fromHDpatients (Schapira, 1998; Tabrizi et al., 1999). Accordingly,
the expression of two subunits of the complex II is decreased in the
striatum of HD patients, affecting the dehydrogenase activity of the
complex (Benchoua et al., 2006). A small decrease in complex IV in brain
samples was also reported (Browne et al., 1997; Gu et al., 1996; Schapira,
1998; Tabrizi et al., 1999).
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activity of mitochondrial complex I (Arenas et al., 1998) and
complexes II–III (Ciammola et al., 2006; Turner et al., 2007) along
with mitochondrial depolarization, cytochrome c release and in-
creased caspases activity (Ciammola et al., 2006; Turner et al., 2007)
in skeletal muscle. In platelets from HD patients, some authors found
a decrease in complex I activity (Parker et al., 1990), whereas others
reported no changes in the activity of mitochondrial complexes (Gu
et al., 1996; Powers et al., 2007a). Moreover, the phosphocreatine/
inorganic phosphate ratio was signiﬁcantly decreased in restingmuscle
(Koroshetz et al., 1997) of HDpatients, evidencing bioenergetic changes
in HD peripheral tissues.
These data suggest the involvement of mitochondrial defects in HD
pathogenesis. Mutant huntingtin may cause mitochondrial dysfunc-
tion by either perturbing transcription of nuclear-encoded mitochon-
drial proteins or by directly interacting with the organelle, thus
evoking defects in mitochondrial dynamics, organelle trafﬁcking and
ﬁssion and fusion, which, in turn, may result in bioenergetic failure in
HD (Bossy-Wetzel et al., 2008). In fact, mutant huntingtin was
previously shown to interact with neuronal mitochondria of YAC72
transgenic mice (Panov et al., 2002), suggesting that mitochondrial
calcium abnormalities associatedwith HD pathogenesismay be due to
a direct effect ofmutant huntingtin on the organelle (Choo et al., 2004;
Panov et al., 2002).
Moreover, mutant huntingtin fragments can directly induce the
opening of the mitochondrial permeability transition pore in isolated
mouse liver mitochondria, with the consequent release of cytochrome
c, as well as a decrease in the calcium threshold necessary to induce it
(Choo et al., 2004), favoring the hypothesis that mutant huntingtin
interacting with mitochondria may well lead to mitochondrial
modiﬁcations independently of damage on mtDNA.
Mitochondria from lymphoblasts of HDpatients have been shown to
present increased susceptibility to apoptotic stimuli due to an abnormal
mitochondrial transmembrane potential (Sawa et al., 1999). Lympho-
blasts derived from HD patients also showed increased stress-induced
apoptotic cell death associated with caspase-3 activation, abnormal
calcium homeostasis and mitochondrial dysfunction (Bezprozvanny
and Hayden, 2004; Panov et al., 2002; Sawa et al., 1999). Previously, we
demonstrated that HD human peripheral blood cells, particularly B
lymphocytes, are endowed with increased expression of Bax and
decreased mitochondrial membrane potential (Almeida et al., 2008),
further suggesting that an adverse effect of mutant huntingtin is not
limited to neurons.
In addition, we previously found that HD cybrids, obtained from
the fusion of HD platelets with NT2 rho0 cells, depleted of
mitochondrial DNA, do not exhibit signiﬁcant modiﬁcations in the
activity of mitochondrial respiratory chain complexes I–IV or in
mtDNA sequence variations, suggestive of a primary role in
mitochondrial susceptibility in the subpopulation of HD carriers
studied (Ferreira et al., 2010). In accordance, Swerdlow et al. (1999)
showed that HD cybrids did not present changes in mitochondrial
respiratory chain activity, oxidative stress or calcium homeostasis.
Conversely, increased mitochondrial Bim and Bak levels, and a
slight release of cytochrome c in untreated HD cybrids explained
their moderate susceptibility to mitochondrial-dependent apoptosis
(Ferreira et al., 2010). These changes were translated into increased
susceptibility of HD cybrids to undergo mitochondrial-dependent
apoptosiswhen subjected to complex II inhibitionwith3-nitropropionic
acid (3-NP) or to apoptosis elicited by the classic inducer staurosporine
(Ferreira et al., 2010). Despite unchanged activity of mitochondrial
complexes, this cell model presented evidences of mitochondrial
dysfunction based on signiﬁcant changes on mitochondrial membrane
potential and increased ROS generation. Taking into account our
previous data and the importance of metabolic defects in HD
pathogenesis, the aim of this studywas to investigate changes in energy
metabolism in HD human cybrid lines.Materials and methods
Materials
Opti-MEM was purchased from GIBCO (Paisley, UK). RPMI-1640,
protease inhibitor cocktail (chymostatin, pepstatin A, leupeptin and
antipain), 3-NP and penicillin/streptomycin, β-Nicotinamide adenine
dinucleotide hydrate (NAD), thiamine pyrophosphate (TPP), CoASH,
sodium pyruvate, malate, citrate synthase from porcine heart, acetyl-
CoA, β-Nicotinamide adenine dinucleotide phosphate hydrate
(NADP), glucose 6-phosphate and maleimide were from Sigma
Chemical Co. (St Louis, MO, USA). All other reagents were of analytical
grade.
Cybrid production, culture and incubation with 3-NP
Cybrids (cytoplasmic hybrid systems) were produced after fusion
of mitochondrial DNA-depleted human teratocarcinoma cells (rho0
NT2 cells, obtained from Dr. R. H. Swerdlow, University of Virginia,
Charlottesville, VA, USA), with human platelets isolated from six
genetically and clinically conﬁrmed HD patients (42–44 CAG repeats)
from pre-identiﬁed Portuguese families and three age-matched
healthy controls (without any neurological disease) as described in
Ferreira et al. (2010). Cybrids were cultured in Opti-MEM medium
supplemented with 10% fetal calf serum, penicillin (100 U/ml),
streptomycin (100 μg/ml) and maintained at 37 °C in humidiﬁed
incubator containing 95% air and 5% CO2. Experiments were
performed with cybrids less than 2 months in culture, as previously
described by us (Ferreira et al., 2010). In experiments aiming to
inhibit glycolysis, the commonly used culture medium (Opti-MEM)
was replaced by RPMI medium with (+Gluc) or without glucose. In
some experiments, 2 μg/ml oligomycin was added to glucose-
containing or glucose-free medium in order to inhibit mitochondrial
ATP synthesis. In another set of experiments, RPMI without glucose
was supplemented with 2 mM 2-deoxy-D-glucose (+2-DOG), a
competitive inhibitor of glucose metabolism (Wick et al., 1957), and
cellsweremaintained in thesemedia for 8 h prior to the experiments. To
further analyze the importance the glycolytic metabolism in cell
bioenergetic status, in some experiments RPMImediumwithout glucose
plus 2-DOGwas supplemented with 10 mM pyruvate (2-DOG+Pyr) to
directly feed the mitochondria.
Cybrids were plated onmultiwell chambers or ﬂasks at a density of
0.06×106 cells/cm2, one day before the experiments, in order to allow
the desired conﬂuence. Where indicated, cells were incubated in
culture medium in the absence or presence of 3-NP (0.1, 1 or 10 mM)
for 24 h or in the absence or presence of metabolic inhibitors, for 8 h,
as described in ﬁgure legends.
Measurement of ATP and phosphocreatine
Cells were washed with ice-cold PBS, scraped, and extracted with
0.6 M perchloric acid, supplemented with 25 mM EDTA-Na+, and
centrifuged at 20,800 g for 5 min at 4 °C. The resulting pellet was
solubilized with 1 M NaOH and further analyzed for total protein
content by the Bio-Rad Protein assay. After neutralization with 3 M
KOH/1.5 M Tris, samples were centrifuged at 20,800 g for 5 min at
4 °C. The resulting supernatants were assayed for ATP determination
by separation in a reverse-phase high-performance liquid chroma-
tography (HPLC), with detection at 254 nm, as described previously
(Stocchi et al., 1985). ADP and AMP levels were undetectable in our
samples. Peak identity was determined by the retention time
compared with standards and the amount of ATP was determined
by using a concentration standard curve. These samples were also
used to determine intracellular phosphocreatine levels, by following
NADP+ reduction at 340 nm, mediated by ATP production by creatine
kinase, in the presence of hexokinase and glucose-6-phosphate
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SpectraMax Plus 384 (Molecular Devices, USA), according to a
previously described method (Heinz and Weißer, 1985). The results
were expressed in pmol phosphocreatine or ATP per mg protein and
converted in percentage of controls.Assessment of intracellular pyruvate and lactate
Cells were washed with ice-cold PBS and extracted with 0.6 M
perchloric acid supplementedwith 25 mMEDTA-Na+. Cell extractswere
centrifuged at 20,800 g for 5 min at 4 °C in order to remove cell debris.
Lactate and pyruvate were determined in the supernatant by using kits
from Randox Laboratories (Antrim, U.K.) and Ben SRL (Milan, Italy),
respectively. Results of lactate and pyruvate content were obtained in
pmol/mg protein and expressed as a ratio of lactate/pyruvate.Quantiﬁcation of mitochondrial NADH/NADt ratio
Cells were washed in ice-cold PBS, extracted in sucrose buffer and
then homogenized by using a Thomas USA 0872 potter, at 4 °C. Extracts
were then centrifugedat560 g in order to removenucleardebris and the
resulting supernatant was centrifuged at 12,000 g for 20 min at 4 °C in
order to obtain mitochondrial sediment. Mitochondrial fraction was
ressuspended in a medium containing 20 mM NaHCO3, 100 mM
Na2CO3, 10 mM nicotinamide and 0.05% Triton X-100 at 4 °C and
centrifuged at 15,300 g for 5 min at 4 °C. An aliquot of the supernatant
was then incubated at 60 °C for 30 min in order to selectively
decompose the thermo sensible NAD+. The remaining supernatant
was kept on ice until the determination of total NAD (NADt). Aliquots of
50 μl were then incubated with 840 μl reaction buffer containing:
100 mM Tris, pH 7.8; 5 mM EDTA, 0.5 mM 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT), 0.2 mg/ml alcohol dehy-
drogenase and 10 μl N-ethyldibenzopyrazine ethyl sulfate salt (PES)
200 mM for 5 min at 25 °C, and then 100 μl of 6 M ethanol was added to
each sample. Extracts were centrifuged at 15,300 g for 30 s at 25 °C and
quantiﬁed by using a colorimetric assay based on MTT reduction that
occurs at 570 nmduring2 min (Umemura andKimura, 2005) by using a
microplate reader Spectra Max Plus 384 (Molecular Devices, USA).
Protein was quantiﬁed by BioRad protein assay (Bradford method) and
results normalized as pmol/mg protein, and presented as NADH/NADt
ratio.Tricarboxylic acid cycle (TCA) enzymatic activities
Pyruvate, alpha-ketoglutarate and malate dehydrogenases activ-
ities were measured as described previously (Nulton-Persson and
Szweda, 2001; Starkov et al., 2004; Zhou et al., 2008). Total cell
extracts were obtained using 0.05 mg/ml in 25.0 mM KH2PO4 and
0.5 mM EDTA, pH 7.25, containing 0.01% Triton X-100 and protein
quantiﬁed using BioRad protein assay. Enzyme activities were
determined by following the rate of NADH formation at 340 nm by
using a microplate reader Spectra Max Plus 384 (Molecular Devices,
USA). For pyruvate dehydrogenase (PDH), 15 μg of cell sample were
mixed with 2.5 μM rotenone, 0.5 mM of NAD+, 0.2 mM thiamine
pyrophosphate (TPP+), 0.04 mM CoASH, and 4 mM pyruvate (Zhou
et al., 2008). For alpha-ketoglutarate dehydrogenase (KGDH) activity,
15 μg of cell sample were mixed with 0.3 mM TPP+, 10 mM CaCl2,
0.2 mM MgCl2, 5 mM alpha-ketoglutarate (KG), 1 μM rotenone,
0.2 mM NAD+, and 0.14 mM CoASH (Starkov et al., 2004). For malate
dehydrogenase activity, 15 μg of protein were used and mixed with
40 μM rotenone, 5 mM MgCl2, 25 mM malate, 1 unit/ml of citrate
synthase, 0.3 mM acetyl-CoA, and 10 mMNAD+ (Nulton-Persson and
Szweda, 2001). The activities were calculated as the absorbance units
per min and per mg protein.Measurement of G6PD activity
G6PD activity was determined according to Choo et al. (2005),
with some minor modiﬁcations. Brieﬂy, cell samples (30 μg) were
transferred to a 96-well plate containing 150 μL of reaction buffer
containing: 0.38 mM NADP+, 6.3 mM MgCl2, 3.3 mM glucose-6-
phosphate, and 5 mM maleimide (to inhibit 6-phosphogluconate
dehydrogenase -6PGD- activity) in 50 mM Tris–HCl (pH 7.5) and the
total volume of 200 μL was adjusted with water. NADPH production
was continuously monitored at 340 nm, using a microplate reader
Spectra Max Plus 384 (Molecular Devices, USA) at 37 °C, and the
activity was calculated in absorbance units per min per mg protein.Determination of pyuvate dehydrogenase (PDH) E1α subunit protein
levels and phosphorylation
PDH expression and phosphorylation were assessed using a kit
from MitoSciences (Oregon, USA) following the manufacturer in-
structions and using the solutions provided in the kit. Brieﬂy, cells
were plated at conﬂuent density, allowed to adhere, and ﬁxed with
3.7% formaldehyde/4% sucrose. Cells were permeabilized, blocked and
incubated with total PDH E1α combined with another antibody
against the phosphorylated forms of PDH E1α at pSer 232, pSer293 or
pSer 300, and developed by dual colorimetric detection. Cell density
was normalized after Janus Green staining. Absorbance was moni-
tored using a microplate reader Spectra Max Plus 384 (Molecular
Devices, USA).Assessment of mitochondrial levels of aspartate, glutamate, glutamine
and alanine by HPLC
The levels of the amino acids aspartate, glutamate, glutamine and
alanine were measured in mitochondrial fractions obtained from CTR
and HD cybrids, prepared as described for the analysis of mitochon-
drial NADH/NADt ratio. Mitochondrial pellets were resuspended in
1 M NaOH.
The amino acids were analyzed in a Gilson-ASTED HPLC system.
Sampleswere separated on a HichromACE type column (150×4.6 mm,
5 μMC18) at aﬂowrate of 2.5 ml/min for 45 min, usinga ternary solvent
system consisting of solvent A [37.5 mM sodium phosphate, 50 mM
propionic acid, 7% acetonitrile, and 3% dimethyl sulfoxide (pH 6.2)],
solvent B (40% acetonitrile, 33% methanol, and 7% dimethyl sulfoxide),
and solvent C [62.5 mM sodium phosphate, 50 mM propionic acid, 7%
acetonitrile, and 3% dimethyl sulfoxide (pH 5.5)]. The amino acids were
detected as ﬂuorescent derivatives after precolumn derivatization with
o-phthaldialdehyde/2-mercaptoethanol (OPA/MCE), using a Gilson
ﬂuorescent detectormodel 121,with excitation at 340 nmand emission
at 410 nm. Amino acid concentration was determined by comparison
with peak areas of amino acid standards, and expressed in nanomol per
mg of protein. Protein levels were determined by the BioRad protein
assay.Statistical analysis
No signiﬁcant differences in biochemical studies were observed
between the six HD cybrid lines and between the three CTR cybrids
used in this work. Therefore data were expressed as themean±S.E.M.
of the number of experiments indicated in the ﬁgure legends.
Comparisons between multiple groups were performed with a two-
way analysis of variance (ANOVA), followed by Bonferroni post-test
for comparison between experimental groups. Student's t test was
also performed for comparison between two Gaussian populations, as
described in ﬁgure legends. Signiﬁcance was accepted at pb0.05.
Fig. 2. Glycolysis and pentose-phosphate pathways in control (CTR) and HD cybrids.
A) Intracellular lactate/pyruvate ratio levels. Cells were incubated for 8 h in glucose-
containing medium (RPMI+Gluc) or upon glycolysis inhibition achieved in the
absence of added glucose and in the presence of 2 mM 2-deoxyglucose (+2-DOG).
B) Activity of glucose-6-phosphate dehydrogenase, a key enzyme of the pentose
phosphate pathway. Cell samples obtained from CTR and HD cybrids were used to
evaluate the reduction of NADP+ by G6PD. Data are expressed as the mean±S.E.M.
from 4 to 8 independent experiments performed in duplicate or triplicate. Statistical
analysis was performed by Student's t test; t Pb0.05, when compared to CTR Cyb
(+Gluc) or by two-way ANOVA followed by Bonferroni post test * Pb0.05 when
compared to CTR Cyb (+Gluc); ## Pb0.01 when compared to the HD Cyb (+Gluc).
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Glycolysis is stimulated in HD cybrids
We initially characterized the energy metabolism in HD cybrid
lines derived from symptomatic HD patients. Intracellular ATP levels
were analyzed in order to evaluate the bioenergetic status of HD
versus CTR cybrids in the absence or in the presence of 3-NP (Fig. 1). In
both basal and in 0.1 mM 3-NP-treated conditions, HD cybrids
presented a signiﬁcant increase in total ATP levels when compared
with CTR cybrids. Although still being higher in HD cybrids compared
to CTR cybrids, ATP levels slightly decreased in the presence of 1 and
10 mM 3-NP (Fig. 1); no measurable levels of ADP or AMP were
detected in these conditions.
Since we observed an increase in total ATP levels in HD cybrids, the
glycolytic metabolic rate in HD versus CTR cybrids was then compared
before and after glycolysis inhibition, for 8 h (Fig. 2). For this purpose,
the usual cell culture medium Opti-MEM (only commercialized
containing glucose) was changed to RPMI-1640 medium, in order to
allow testing experimental conditions lacking glucose. No differences
were observed in lactate/pyruvate ratio, under basal conditions, in both
cell lines cultured in Opti-MEM or RPMI+Gluc (data not shown).
Interestingly, HD cybrids exhibited increased lactate/pyruvate ratio
compared to CTR cybrids (Fig. 2A), suggesting an increased glycolytic
rate, which may underlie increased ATP production in HD cybrids.
Indeed, the difference in lactate/pyruvate ratio in HD and CTR cybrids
was abolished upon glycolysis inhibition, achieved by adding 2-DOG to
glucose-free medium (Fig. 2A), further suggesting a higher role for
glycolysis in HDcybrid bioenergetics. Indeed, lactate/pyruvate ratiowas
decreased in CTR cybrids in response to glycolysis inhibition, and largely
decreased in HD cybrids (Fig. 2A). HD cells also showed a decreased
activity of G6PD, a key enzyme of the pentose phosphate pathway
(Fig. 2B), suggesting that in HD cybrids glucose is preferentially
metabolized through the glycolytic pathway.
Partial dysfunction in mitochondrial bioenergetics underlies the
stimulation of glycolytic pathway in HD cybrids
In order to determine the importance of the glycolytic pathway for
ATP production in these cells, we further examined the changes in ATP
levels in CTR and HD cybrids before and after glycolysis or ATP
synthase inhibition. Glucose-free medium supplemented with 2-DOG,
previously shown to inhibit glycolysis (Fig. 2), largely and signiﬁ-
cantly decreased the intracellular levels of ATP in HD cybrids, in
contrast with CTR cybrids (Fig. 3A). Inhibition of ATP synthase with
oligomycin in the presence of glucose decreased ATP production inFig. 1. Endogenous ATP levels in control (CTR) and HD human cybrids under basal
conditions and after exposure to 3-NP. Cells were incubated in the absence (basal) or in
the presence of 0.1, 1 and 10 mM 3-NP for 24 h. Intracellular ATP was determined by
HPLC as described in Materials and methods. Data are expressed as the mean±S.E.M.
from 6 to 8 independent experiments performed in duplicates. Statistical analysis was
performed by t test; t Pb0.05 when compared to the respective CTR Cyb.HD, compared to CTR cybrids, and no difference was observed
between the two cell lines (Fig. 3A). In the absence of glucose, cells
can use exogenous pyruvate (or lactate) to generate ATP by oxidative
phosphorylation (Budd and Nicholls, 1996; Rego et al., 2001b).
Interestingly, we observed that metabolically feeding mitochondria
with pyruvate under conditions of glycolysis inhibition did not
recover ATP levels in HD cybrids (Fig. 3A). Inhibition of ATP synthase
in the absence of active glycolysis drastically decreased ATP levels in
both HD and CTR cybrids. Slight changes in ATP levels caused by 2-
DOG (in glucose-free medium) and pyruvate, were observed in CTR
cybrids.
We further examined the contribution of phosphocreatine, which
constitutes a reservoir for rapid ATP regeneration, in HD and CTR
cybrids (Fig. 3B). Upon glycolysis inhibition, phosphocreatine levels
signiﬁcantly decreased in HD cybrids, whereas a moderate decrease
was observed in CTR cybrids, suggesting that phosphocreatine
contributes to maintain the levels of ATP in HD cybrids subjected to
glycolytic inhibition (Fig. 3B). Since glycolysis activation may occur in
cells exhibiting decreased mitochondrial metabolic efﬁciency, we
determined phosphocreatine levels after supplying mitochondria
with pyruvate. In these conditions, phosphocreatine levels were also
decreased in HD cybrids, in contrast with CTR cybrids, further
suggesting an important role for phosphocreatine in maintaining
cellular ATP levels (Fig. 3B). These data reveal the cellular inter-
dependence of these two rapid generating energy metabolic path-
ways. These observations not only suggest that HD cybrids have
increased glucose oxidation rate, but also that this may be a
compensatory response to maintain cellular ATP levels. However,
inhibition of ATP synthase with oligomycin did not affect phospho-
creatine levels either in the presence or in the absence of glycolysis, in
CTR or HD cybrids. The inability of pyruvate to restore ATP or
Fig. 3. Analysis of total intracellular ATP and phosphocreatine levels in HD and CTR
cybrids before and after glycolysis or ATP synthase inhibition and pyruvate
supplementation. Cells were incubated in the presence (+Gluc) or in the absence
(plus 2-deoxyglucose, +2-DOG) of glucose in order to inhibit glycolysis, with or
without oligomycin (+Gluc+Oligo or +2-DOG+Oligo) in order to inhibit ATP
synthase. Pyruvate was added to directly ‘feed’ the mitochondria (RPMI+2-DOG+Pyr).
Data are expressed as the mean±S.E.M. from 4 to 6 independent experiments performed
in duplicate. Statistical analysis was performed by two-way ANOVA, followed by
Bonferroni post test. * Pb0.05, *** Pb0.01 when compared to the respective CTR Cyb;
# Pb0.05, ## Pb0.01, ### Pb0.001 when compared to the appropriate basal (+Gluc)
condition.
131I.L. Ferreira et al. / Experimental Neurology 231 (2011) 127–134phosphocreatine levels suggest decreased mitochondrial metabolic
efﬁciency in HD cybrids.
Mitochondrial bioenergetics in HD cybrids is impaired due to PDH
dysfunction
Taking into account that the activity of mitochondrial electron
transport chain (ETC) complexes is maintained in HD cybrids
(Ferreira et al., 2010) and that increased rate of glycolytic activity
appears to exceed the capacity for oxidative metabolism in these cells,
we hypothesized that HD cybrids had compromised mitochondrialFig. 4. Mitochondrial NADH levels. Quantiﬁcation of NADH/NADt ratio was performed in
mitochondrial extracts from HD Cyb or CTR Cyb. Data are expressed as the mean±S.E.M.
from 4 to 6 independent experiments performed in duplicate. Statistical analysis was
performed by Student's t test. tt Pb0.01, when compared to CTR Cyb.function at the level of dehydrogenase enzymes associated with the
TCA cycle. Thus, we measured NADH/NADt ratio in mitochondrial
extracts from HD and CTR cybrids (Fig. 5). Our results show a
signiﬁcant decrease in mitochondrial NADH/NADt levels in HD
cybrids, suggesting a dysfunction in mitochondrial dehydrogenases.
Therefore, we determined the activity of PDH, KGDH (two highly
regulated irreversible enzymes) and malate dehydrogenase (Fig. 5),
which are responsible for producing a large proportion of mitochon-
drial NADH for complex I usage at mitochondrial ETC. In accordance
with the inefﬁciency of pyruvate to restore ATP levels in HD cybrids,
resulting in the stimulation of glycolysis in these cells, we observed a
signiﬁcant decrease in the PDH activity (Fig. 5A), which may explain
the decrease in NADH/NADt (Fig. 4). Importantly, the decrease in PDH
activity in HD cybrids was accompanied by a decrease in PDH E1α
subunit protein expression levels (Fig. 6A). Phosphorylation of E1α
subunit in HD cybrids may also contribute for a decrease in PDH
activity, since a tendency for an increase in pSer232 and pSer293 PDH
E1α subunit was observed in these cybrids (Fig. 6B).
Nevertheless, the activity of KGDHwas increased in HD versus CTR
cybrids (Fig. 5B), suggesting a compensatory mechanism to counter-
balance the decrease in NADH production through the PDH. However,
malate dehydrogenase activity was similar in HD and CTR cybrids,Fig. 5. Activity of dehydrogenases of the mitochondrial matrix. Total extracts were
prepared from HD or CTR cybrids, and analyzed for the enzymatic activity of pyruvate
dehydrogenase (PDH) (A), alpha-ketoglutarate dehydrogenase (KGDH) (B) and malate
dehydrogenase (C). Data are expressed as the mean±S.E.M. from 4 to 6 independent
experiments performed in duplicates. Statistical analysis was performed by Student's
t test. t Pb0.05, ttt Pb0.001, when compared to CTR Cyb.
Fig. 6. Pyruvate dehydrogenase (PDH) E1α subunit expression and phosphorylation.
The protein expression levels and the phosphorylation of PDH subunit E1α were
assessed using a kit, as described in Materials and Methods. Total PDH E1α expression
(A) and phosphorylated forms of PDH E1α at pSer 232, pSer293 or pSer 300
(B) were analyzed in CTR or HD cybrids. Statistical analysis was performed by Student's
t test; tt Pb0.01 compared with CTR cybrids. Data are the mean±S.E.M of total PDH
E1α/Janus Green or phosphorylated form/total PDH E1α.
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anaplerotic reactions are taking place at the level of KGDH. One of
these reactions is catalyzed by glutamate dehydrogenase, which
converts glutamate into KG and generates NH4+. Thus, we next
examined themitochondrial levels of aspartate and glutamate (Fig. 7).
The results indicate that although aspartatemitochondrial levels were
similar in HD and CTR cybrids, mitochondria of HD cybrids presented
higher levels of glutamate (Fig. 7), which may underlie the increase in
KGDH activity (Fig. 5B). Furthermore, no changes in glutamine were
observed in HD versus CTR cybrids (Fig. 7), excluding possible
conversion of glutamine-glutamate by mitochondrial glutaminase;
indeed, this enzyme may balance with the activity of glutamineFig. 7. Mitochondrial amino acid levels. The levels of alanine, aspartate, glutamate and
glutamine were measured by HPLC in mitochondrial extracts from CTR or HD cybrids, as
described inMaterials andMethods. Statistical analysiswas performed by Student's t test;
t Pb0.05 compared with CTR cybrids. Data are the mean±S.E.M. of 6–7 independent
experiments.synthase, which detoxiﬁes NH4+. Conversely, mitochondrial levels of
alanine were decreased, suggesting increased glutamate generation
through the activity of alanine transaminase, which was previously
described to be present in the mitochondrial matrix (DeRosa and
Swick, 1975), apart from its most frequently reported cytosolic
subcellular location. The results are summarized in Fig. 8.Discussion
In this work we show that mitochondrial bioenergetics of HD
cybrids, an ex-vivo human peripheral cell model in which the
contribution of mitochondrial defects from HD patients is isolated, is
compromised when compared with CTR cybrids.
Mitochondrial dysfunction is considered a common feature in the
pathogenesis of neurodegenerative disorders like HD (Kim et al.,
2010; Oliveira, 2010; Parker et al., 1990). Mitochondrial dysfunction
constitutes a cellular hallmark for neurodegeneration and occurs as a
consequence of defective mitochondrial composition, trafﬁcking to
synapses, calcium handling, ATP production, transcription abnormal-
ities and/or ETC impairment (Rosenstock et al., 2010). Overexpression
of mutant huntingtin, but not the normal protein, increases oxidative
stress-induced mitochondrial fragmentation in HeLa cells, which
correlates with increased caspase-3 activation and cell death (Wang
et al., 2009). Moreover, both mitochondrial loss and altered
mitochondrial morphogenesis with increased mitochondrial ﬁssion
and reduced fusion have been described in moderate-to-severe grade
HD patients' striatal neurons (Kim et al., 2010). Furthermore,
overexpression of proteins that stimulate mitochondrial fusion
attenuates the toxicity of Htt proteins containing expanded poly-
glutamine tracts in both cells and animals (Wang et al., 2009).Fig. 8. Bioenergetic dysfunction in HD cybrids, in comparison with CTR cybrids. In HD
cybrids glycolysis is stimulated, whereas the pentose phosphate pathway is inhibited.
Mitochondrial NADH/NADt levels are decreased due to a decrease in PDH activity and
protein levels, although KGDH is stimulated, along with an increase in mitochondrial
glutamate levels and a decrease in mitochondrial alanine levels. Phosphocreatine levels
contribute to maintain high ATP levels in HD cybrids under glycolysis inhibition
conditions. For details see text. Ala- alanine; Asp- aspartate; CK- creatine kinase; Cr-
creatine; GDH- glutamate dehydrogenase; Glu- glutamate; KGDH- alpha-ketoglutarate
dehydrogenase; αKG- alpha ketoglutarate; Lac- lactate; LDH- lactate dehydrogenase;
Mal- malate; MDH- malate dehydrogenase; OA- oxaloacetate; P-Cr- phosphocreatine;
PDH- pyruvate dehydrogenase; Pyr- pyruvate.
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dysfunction, being the cybrid technique an interesting approach (King
and Attardi, 1989). We recently showed that HD cybrids heighten
vulnerability to 3-NP-induced oxidative stress, mitochondrial cyto-
chrome c release and cell death, when compared to CTR cybrids
(Ferreira et al., 2010). The analysis of the bioenergetic status of HD
cybrids presented in this work reveals that endogenous ATP levels are
signiﬁcantly higher than those present in CTR cybrids. Moreover, that
difference was partially refrained upon exposure to 1 or 10 mM 3-NP.
The decrease in endogenousATP levels inHDcybrids exposed to 10 mM
3-NPmight be related to the increase in apoptotic cell death observed in
these conditions (Ferreira et al., 2010). We also demonstrated that
untreated HD cybrids do not exhibit signiﬁcant modiﬁcations in the
activity of mitochondrial respiratory chain complexes I–IV, but are
endowed with a slight decrease in mitochondrial membrane potential,
compared with CTR cybrids (Ferreira et al., 2010). Interestingly, the
same HD cybrid lines exhibited increased ATP levels, which were
correlated with increased lactate/pyruvate ratio; this ratio decreased
upon glycolysis inhibition, revealing increased glycolytic metabolism in
HD cybrids. Still, under these conditions, mitochondria supported
remaining ATP generation.
Modiﬁed glycolytic energy metabolism has been described in HD
patients, both in central and in peripheral tissues, as suggested by
high levels of lactate in the striatum (Jenkins et al., 1993) and in the
cortex (Jenkins et al., 1993; Koroshetz et al., 1997), increased lactate/
pyruvate ratio in the CSF (Koroshetz et al., 1997), but decreased
astrocytic glucose metabolism in the striatum with preserved oxygen
metabolism in early symptomatic HD patients (Powers et al., 2007b).
Moreover, the activity of G6PD, a key enzyme of the pentose
phosphate pathway, was decreased in HD cybrids, suggesting that
glucose metabolization occurs through the glycolytic pathway. A
decrease in total ATP production was further observed in HD cybrids
subjected to glycolysis inhibition. Although phosphocreatine levels
were shown to be similar between HD and CTR cybrids, glycolysis
inhibition signiﬁcantly increased phosphocreatine consumption in HD
cybrids. Phosphocreatine hydrolysis may compensate for the decrease
in intracellular ATP levels, since it can function as an alternative
energy supply. Nevertheless, unchanged phosphocreatine was ob-
served after inhibition of mitochondrial ATP generation with
oligomycin. Previous studies showed low levels of phosphocreatine/
inorganic phosphate ratio in muscle of HD patients compared to
control subjects (Lodi et al., 2000) and a delayed recovery of
phosphocreatine levels in HD patients in response to exercise (Saft
et al., 2005). Peripherally, a signiﬁcant decrease in phosphocreatine/
inorganic phosphate ratio was found in resting muscle (Koroshetz et
al., 1997) of HD patients. Furthermore, pyruvate supplementation
(previously shown to stimulatemitochondrial activity in conditions of
glycolysis inhibition (e.g. Oliveira et al., 2006; Rego et al., 2001a), did
not recover HD cybrids ATP levels. Furthermore, we demonstrated
that mitochondrial NADH/NADt ratio, a parameter that reﬂects
mitochondrial redox status, is decreased in HD cybrids, pointing out
the presence of alterations in mitochondrial function upstream
oxidative phosphorylation in these cells. The decrease in mitochon-
drial NADH/NADt may explain the decrease in mitochondrial
membrane potential in HD cybrids, compared to CTR cybrids, despite
maintained activity of mitochondrial complexes I–IV (Ferreira et al.,
2010). Because these HD cybrid lines are endowed with preserved
activity of ETC complexes, the present data suggest a deregulation of
mitochondrial function in HD cybrids, upstream the mitochondrial
respiratory chain.
At the mitochondrial level, NADH production largely depends on
the activity of mitochondrial dehydrogenases, such as PDH, and the
TCA enzymes isocitrate dehydrogenase, KGDH and malate dehydro-
genase. We observed a large decrease in the activity of PDH in HD
cybrids. Nevertheless, the activity of KGDH was increased, suggesting
a compensatory mechanism to counterbalance the decrease in NADHproduction through the PDH. Mitochondrial dehydrogenases are
highly regulated enzymes. The activity of these proteins may be
affected by availability of substrates and cofactors or by altered
expression of the enzymes (Salway, 2006). The activity of mitochon-
drial dehydrogenases may be also allosterically (e.g. by Ca2+, ATP/
ADP, NADH/NAD+) or covalently affected. Covalent modiﬁcations
that affect enzyme activity include phosphorylation or oxidation. PDH
is inhibited by phosphorylation of its E1 alpha subunit and under
oxidative stress conditions (Martin et al., 2005). In the present study
we show decreased protein levels and increased (although not
signiﬁcantly) Ser phosphorylation of PDH E1α subunit, which could
underlie the decline in PDH activity. Indeed, decreased PDH activity
was observed in the caudate and putamen of HD patients (Sorbi et al.,
1983). Decreased PDH complex detected in HD patient's caudate
nucleus was further correlated with increasing duration of the illness
(Butterworth et al., 1985). Moreover, PDH expression was shown to
decrease with age in the striatum of R6/2 transgenic mice (Perluigi
et al., 2005). Previously, we also showed that HD cybrids present
increased ROS production, compared to CTR cybrids (Ferreira et al.,
2010); therefore we cannot exclude modiﬁcations in PDH activity
resulting from enzyme oxidation.
KGDH, another important mitochondrial dehydrogenase, belongs
to the same family of PDH complex and shares the same NADH
producing subunit, E3 (Gibson et al., 2005). Similarly to PDH, KGDH is
affected by oxidative stress, being a mediator between mitochondria
and oxidative stress in neurodegeneration (Gibson et al., 2005).
Decreased KGDH activity was previously described in Alzheimer's and
Parkinson's diseases (Gibson et al., 2000); however, and in contrast
with PDH, no changes have been reported in HD. KGDH catalyzed
reaction is important for energy production, neurotransmitter
metabolism (e.g. glutamate) and metabolic interaction between
mitochondria and cytosol. KGDH is also a critical point of TCA
regulation, linking mitochondrial bioenergetics to amino acid syn-
thesis and degradation (Gibson et al., 2005). KGDH uses KG produced
in the TCA during oxidation of carbohydrates and fatty acids. When
the TCA rate is lower than necessary, one way of replenishing TCA
intermediaries is through glutamate conversion into KG by mito-
chondrial glutamate dehydrogenase, which also produces NADH.
Since, in our conditions, the TCA does not receive enough input via
PDH, KGDHmay be a point of entry of TCA intermediaries. In addition,
KG may also be produced by transamination of glutamate as part of
the malate-aspartate shuttle that transfers reducing equivalents from
the cytoplasm to the mitochondria (Gibson et al., 2005). Alteration of
glutamate synthesis, metabolism and/or transport in HD cybrids is
suggested by the observed increase inmitochondrial glutamate levels,
while mitochondrial aspartate levels were unchanged. Although
aspartate-glutamate conversions through transamination and gluta-
mine–glutamate deamidation are unlikely to contribute for the
increase in mitochondrial glutamate pool, we found a decrease in
alanine in mitochondrial subcellular extracts, favoring an increased
activity of alanine transaminase. Indeed, mitochondrial glutamate is
used by alanine aminotransferase in the mitochondrial matrix to
produce pyruvate, by converting KG and alanine into glutamate and
pyruvate. In agreement, alanine levels were found to be decreased in
the CSF of HD patients, along with decreased pyruvate levels and
increased lactate/pyruvate ratio (Koroshetz et al., 1997). A decrease in
mitochondrial alanine levels, as an attempt to recover KG levels and
thus mitochondrial NADH, may explain the increase in glutamate
levels observed under our experimental conditions.
In conclusion, our results show that HD cybrid lines possess
inherent bioenergetically dysfunctional mitochondria derived from
HD patients' platelets in an otherwise functional nuclear background.
Mitochondrial dysfunction persists at the level of PDH, upstream the
oxidative phosphorylation, affecting amino acid metabolic ﬂuxes and
the cellular bioenergetics through glycolysis stimulation, which
assumes a greater importance in promoting ATP production.
134 I.L. Ferreira et al. / Experimental Neurology 231 (2011) 127–134Acknowledgments
The authors thank the patients and families who generously
contributed to this study. We thank Dr. Sandra M. Cardoso and Dr.
Sandra Almeida (Center for Neuroscience and Cell Biology, CNC, at
University of Coimbra) for helping establishing the HD cybrid lines in
our laboratory, to Dr. Isabel Nunes (CNC) for expert technical assistance
with cell culture maintenance, and Dr. Russell H. Swerdlow (University
of Virginia, Charlottesville, VA, USA) for the gift of rho-zero NT2 cells.
This work was supported by Instituto de Investigação Interdisciplinar,
Universidade de Coimbra, Portugal (Project III/BIO/49/2005), Gabinete
de Apoio à Investigação, Faculdade de Medicina, Universidade de
Coimbra (Project STARTER S-09) and Fundação para a Ciência e a
Tecnologia, Portugal (Projects POCI/SAU-NEU/57310/2004, PTDC/SAU-
FCF/66421/2006 and PTDC/SAU-FCF/108056/2008).
References
Almeida, S., Sarmento-Ribeiro, A.B., Januario, C., Rego, A.C., Oliveira, C.R., 2008. Evidence
of apoptosis and mitochondrial abnormalities in peripheral blood cells of
Huntington's disease patients. Biochem. Biophys. Res. Commun. 374, 599–603.
Arenas, J., Campos, Y., Ribacoba, R., Martin, M.A., Rubio, J.C., Ablanedo, P., Cabello, A.,
1998. Complex I defect in muscle from patients with Huntington's disease. Ann.
Neurol. 43, 397–400.
Benchoua, A., Trioulier, Y., Zala, D., Gaillard, M.C., Lefort, N., Dufour, N., Saudou, F.,
Elalouf, J.M., Hirsch, E., Hantraye, P., Deglon, N., Brouillet, E., 2006. Involvement of
mitochondrial complex II defects in neuronal death produced by N-terminus
fragment of mutated huntingtin. Mol. Biol. Cell 17, 1652–1663.
Bezprozvanny, I., Hayden, M.R., 2004. Deranged neuronal calcium signaling and
Huntington disease. Biochem. Biophys. Res. Commun. 322, 1310–1317.
Bossy-Wetzel, E., Petrilli, A., Knott, A.B., 2008. Mutant huntingtin and mitochondrial
dysfunction. Trends Neurosci. 31, 609–616.
Browne, S.E., Bowling, A.C., MacGarvey, U., Baik, M.J., Berger, S.C., Muqit, M.M., Bird, E.D.,
Beal, M.F., 1997. Oxidative damage and metabolic dysfunction in Huntington's
disease: selective vulnerability of the basal ganglia. Ann. Neurol. 41, 646–653.
Budd, S.L., Nicholls, D.G., 1996. A reevaluation of the role of mitochondria in neuronal
Ca2+ homeostasis. J. Neurochem. 66, 403–411.
Butterworth, J., Yates, C.M., Reynolds, G.P., 1985. Distribution of phosphate-activated
glutaminase, succinic dehydrogenase, pyruvate dehydrogenase and gammagluta-
myl transpeptidase in post-mortem brain from Huntington's disease and agonal
cases. J. Neurol. Sci. 67, 161–171.
Choo, Y.S., Johnson, G.V., MacDonald, M., Detloff, P.J., Lesort, M., 2004. Mutant huntingtin
directly increases susceptibility of mitochondria to the calcium-induced permeability
transition and cytochrome c release. Hum. Mol. Genet. 13, 1407–1420.
Choo, Y.S., Mao, Z., Johnson, G.V., Lesort, M., 2005. Increased glutathione levels in
cortical and striatal mitochondria of the R6/2 Huntington's disease mouse model.
Neurosci. Lett. 386, 63–68.
Ciammola, A., Sassone, J., Alberti, L., Meola, G., Mancinelli, E., Russo, M.A., Squitieri, F.,
Silani, V., 2006. Increased apoptosis, Huntingtin inclusions and altered differenti-
ation in muscle cell cultures from Huntington's disease subjects. Cell Death Differ.
13, 2068–2078.
DeRosa, G., Swick, R.W., 1975. Metabolic implications of the distribution of the alanine
aminotransferase isoenzymes. J. Biol. Chem. 250, 7961–7967.
Ferreira, I.L., Nascimento,M.V., Ribeiro,M., Almeida, S., Cardoso, S.M., Grazina,M., Pratas, J.,
Santos, M.J., Januario, C., Oliveira, C.R., Rego, A.C., 2010. Mitochondrial-dependent
apoptosis in Huntington's disease human cybrids. Exp. Neurol. 222, 243–255.
Gibson, G.E., Park, L.C., Sheu, K.F., Blass, J.P., Calingasan, N.Y., 2000. The alpha-ketoglutarate
dehydrogenase complex in neurodegeneration. Neurochem. Int. 36, 97–112.
Gibson, G.E., Blass, J.P., Beal, M.F., Bunik, V., 2005. The alpha-ketoglutarate-dehydro-
genase complex: a mediator between mitochondria and oxidative stress in
neurodegeneration. Mol. Neurobiol. 31, 43–63.
Gil, J.M., Rego, A.C., 2008. Mechanisms of neurodegeneration in Huntington's disease.
Eur. J. Neurosci. 27, 2803–2820.
Gu,M.,Gash,M.T.,Mann,V.M., Javoy-Agid, F., Cooper, J.M., Schapira,A.H., 1996.Mitochondrial
defect in Huntington's disease caudate nucleus. Ann. Neurol. 39, 385–389.
Heinz, F., Weißer, H., 1985. Creatine phosphate. In: Bergmeyer, H.U., Bergmeyer, J., Graßl,
M. (Eds.), Methods of Enzymatic Analysis, 3rd edition. VCH-Verlagsgesellschaft,
Weinheim, Germany, pp. 507–514.
Jenkins, B.G., Koroshetz, W.J., Beal, M.F., Rosen, B.R., 1993. Evidence for impairment of
energy metabolism in vivo in Huntington's disease using localized 1H NMR
spectroscopy. Neurology 43, 2689–2695.
Kim, J., Moody, J.P., Edgerly, C.K., Bordiuk, O.L., Cormier, K., Smith, K., Beal, M.F., Ferrante,
R.J., 2010. Mitochondrial loss, dysfunction and altered dynamics in Huntington's
disease. Hum. Mol. Genet. 19, 3919–3935.
King, M.P., Attardi, G., 1989. Human cells lacking mtDNA: repopulation with exogenous
mitochondria by complementation. Science 246, 500–503.Koroshetz, W.J., Jenkins, B.G., Rosen, B.R., Beal, M.F., 1997. Energy metabolism defects in
Huntington's disease and effects of coenzyme Q10. Ann. Neurol. 41, 160–165.
Lodi, R., Schapira, A.H., Manners, D., Styles, P., Wood, N.W., Taylor, D.J., Warner, T.T.,
2000. Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease
and dentatorubropallidoluysian atrophy. Ann. Neurol. 48, 72–76.
Martin, E., Rosenthal, R.E., Fiskum, G., 2005. Pyruvate dehydrogenase complex:
metabolic link to ischemic brain injury and target of oxidative stress. J. Neurosci.
Res. 79, 240–247.
Nulton-Persson, A.C., Szweda, L.I., 2001. Modulation of mitochondrial function by
hydrogen peroxide. J. Biol. Chem. 276, 23357–23361.
Olah, J., Klivenyi, P., Gardian, G., Vecsei, L., Orosz, F., Kovacs, G.G., Westerhoff, H.V.,
Ovadi, J., 2008. Increased glucose metabolism and ATP level in brain tissue of
Huntington's disease transgenic mice. FEBS J. 275, 4740–4755.
Oliveira, J.M., 2010. Nature and cause of mitochondrial dysfunction in Huntington's
disease: focusing on huntingtin and the striatum. J. Neurochem. 114, 1–12.
Oliveira, J.M., Chen, S., Almeida, S., Riley, R., Goncalves, J., Oliveira, C.R., Hayden, M.R.,
Nicholls, D.G., Ellerby, L.M., Rego, A.C., 2006. Mitochondrial-dependent Ca2+
handling in Huntington's disease striatal cells: effect of histone deacetylase
inhibitors. J. Neurosci. 26, 11174–11186.
Panov, A.V., Gutekunst, C.A., Leavitt, B.R., Hayden, M.R., Burke, J.R., Strittmatter, W.J.,
Greenamyre, J.T., 2002. Early mitochondrial calcium defects in Huntington's disease
are a direct effect of polyglutamines. Nat. Neurosci. 5, 731–736.
Parker Jr., W.D., Boyson, S.J., Luder, A.S., Parks, J.K., 1990. Evidence for a defect in NADH:
ubiquinone oxidoreductase (complex I) in Huntington's disease. Neurology 40,
1231–1234.
Perluigi, M., Poon, H.F., Maragos, W., Pierce, W.M., Klein, J.B., Calabrese, V., Cini, C., De,
M.C., Butterﬁeld, D.A., 2005. Proteomic analysis of protein expression and oxidative
modiﬁcation in r6/2 transgenic mice: a model of Huntington disease. Mol. Cell.
Proteomics. 4, 1849–1861.
Powers, W.J., Haas, R.H., Le, T., Videen, T.O., Hershey, T., McGee-Minnich, L., Perlmutter,
J.S., 2007a. Normal platelet mitochondrial complex I activity in Huntington's
disease. Neurobiol. Dis. 27, 99–101.
Powers, W.J., Videen, T.O., Markham, J., McGee-Minnich, L., Antenor-Dorsey, J.V.,
Hershey, T., Perlmutter, J.S., 2007b. Selective defect of in vivo glycolysis in early
Huntington's disease striatum. Proc. Natl. Acad. Sci. U. S. A 104, 2945–2949.
Rego, A.C., Vesce, S., Nicholls, D.G., 2001a. The mechanism of mitochondrial membrane
potential retention following release of cytochrome c in apoptotic GT1-7 neural
cells. Cell Death Differ. 8, 995–1003.
Rego, A.C., Ward, M.W., Nicholls, D.G., 2001b. Mitochondria control ampa/kainate
receptor-induced cytoplasmic calcium deregulation in rat cerebellar granule cells. J.
Neurosci. 21, 1893–1901.
Rosenstock, T.R., Duarte, A.I., Rego, A.C., 2010. Mitochondrial-associated metabolic
changes and neurodegeneration in Huntington's disease— from clinical features to
the bench. Curr. Drug Targets 11, 1218–1236.
Saft, C., Zange, J., Andrich, J., Muller, K., Lindenberg, K., Landwehrmeyer, B., Vorgerd, M.,
Kraus, P.H., Przuntek, H., Schols, L., 2005. Mitochondrial impairment in patients
and asymptomatic mutation carriers of Huntington's disease. Mov. Disord. 20,
674–679.
Salway, J.G., 2006. Medical Biochemistry at a Glance 2nd Edition. Wiley-Blackwell.
Sawa, A., Wiegand, G.W., Cooper, J., Margolis, R.L., Sharp, A.H., Lawler Jr., J.F.,
Greenamyre, J.T., Snyder, S.H., Ross, C.A., 1999. Increased apoptosis of Huntington
disease lymphoblasts associated with repeat length-dependent mitochondrial
depolarization. Nat. Med. 5, 1194–1198.
Schapira, A.H., 1998. Mitochondrial dysfunction in neurodegenerative disorders.
Biochim. Biophys. Acta 1366, 225–233.
Sorbi, S., Bird, E.D., Blass, J.P., 1983. Decreased pyruvate dehydrogenase complex
activity in Huntington and Alzheimer brain. Ann. Neurol. 13, 72–78.
Starkov, A.A., Fiskum, G., Chinopoulos, C., Lorenzo, B.J., Browne, S.E., Patel, M.S., Beal, M.F.,
2004. Mitochondrial alpha-ketoglutarate dehydrogenase complex generates reactive
oxygen species. J. Neurosci. 24, 7779–7788.
Stocchi, V., Cucchiarini, L., Magnani, M., Chiarantini, L., Palma, P., Crescentini, G., 1985.
Simultaneous extraction and reverse-phase high-performance liquid chromato-
graphic determination of adenine and pyridine nucleotides in human red blood
cells. Anal. Biochem. 146, 118–124.
Swerdlow, R.H., Parks, J.K., Cassarino, D.S., Shilling, A.T., Bennett Jr., J.P., Harrison, M.B.,
Parker Jr., W.D., 1999. Characterization of cybrid cell lines containing mtDNA from
Huntington's disease patients. Biochem. Biophys. Res. Commun. 261, 701–704.
Tabrizi, S.J., Cleeter, M.W., Xuereb, J., Taanman, J.W., Cooper, J.M., Schapira, A.H., 1999.
Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann.
Neurol. 45, 25–32.
Turner, C., Cooper, J.M., Schapira, A.H., 2007. Clinical correlates of mitochondrial
function in Huntington's disease muscle. Mov. Disord. 22, 1715–1721.
Umemura, K., Kimura, H., 2005. Determination of oxidized and reduced nicotinamide
adenine dinucleotide in cell monolayers using a single extraction procedure and a
spectrophotometric assay. Anal. Biochem. 338, 131–135.
Wang, H., Lim, P.J., Karbowski, M., Monteiro, M.J., 2009. Effects of overexpression of
huntingtin proteins on mitochondrial integrity. Hum. Mol. Genet. 18, 737–752.
Wick, A.N., Drury, D.R., Nakada, H.I., Wolfe, J.B., 1957. Localization of the primary
metabolic block produced by 2-deoxyglucose. J. Biol. Chem. 224, 963–969.
Zhou, Q., Lam, P.Y., Han, D., Cadenas, E., 2008. c-Jun N-terminal kinase regulates
mitochondrial bioenergetics by modulating pyruvate dehydrogenase activity in
primary cortical neurons. J. Neurochem. 104, 325–335.
